Citigroup’s ARK Genomic Revolution ETF ARKG Stock Holding History

Citigroup’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-105,000	Closed	-$2.92M	–	6053
2025 Q3	$2.92M	Hold	105,000	–	–	﹤0.01%	2368
2025 Q2	$2.56M	Hold	105,000	–	–	﹤0.01%	2429
2025 Q1	$2.18M	Hold	105,000	–	–	﹤0.01%	2620
2024 Q4	$2.47M	Hold	105,000	–	–	﹤0.01%	2634
2024 Q3	$2.69M	Hold	105,000	–	–	﹤0.01%	2404
2024 Q2	$2.47M	Buy	+105,000	New	+$2.65M	﹤0.01%	2173
2022 Q3	–	Sell	-29,700	Closed	-$935K	–	5809
2022 Q2	$935K	Buy	+29,700	New	+$1.04M	﹤0.01%	2715
2021 Q4	–	Sell	-242,500	Closed	-$18.1M	–	5807
2021 Q3	$18.1M	Buy	+242,500	New	+$20.3M	0.01%	1063

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Citigroup's ARKG Position: Q1 2026 in Review

Citigroup reduced its ARK Genomic Revolution ETF (ARKG) stake by 33% in Q1 2026, selling an estimated $27.3M and leaving 1,899,044 shares worth $50.2M. The position accounts for 0.02% of the portfolio, ranked #643.

Citigroup first reported a position in ARKG in Q1 2018 and has held it in 33 quarters since. The position peaked at $82M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Citigroup held 1,899,044 shares of ARK Genomic Revolution ETF worth $50.2M as of Q1 2026.
Citigroup sold 931,940 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $27.3M.
ARK Genomic Revolution ETF made up 0.02% of Citigroup's portfolio in Q1 2026, its #643 holding.
Citigroup first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 33 quarters since.
Citigroup's ARK Genomic Revolution ETF position peaked at $82M in Q4 2025.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.